Evidence map›Paper›PMID 42771608›Full record

ArticlePloS one2026

All-atom molecular dynamics simulation of Cyclophilin A in complex with Sanglifehrin A.

Zahra Aliabadi, Alireza Mohebbi

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zahra AliabadiStudent Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Alireza MohebbiDepartment of Virology, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-2489-585X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclophilin A (CypA), a key peptidyl-prolyl cis/trans isomerase, plays a pivotal role in various biological processes and is a target for therapeutic intervention, particularly in viral and cancer-related diseases. This study explores the structural and dynamic effects of Sanglifehrin A (SangfA), a potent CypA inhibitor, using molecular dynamics (MD) simulation. All-atom MD simulations (100 ns) of apo CypA and its complex with SangfA were performed using GROMACS v2023. In addition to MD analyses, essential dynamics, clustering, secondary structure, and binding free energy were analyzed. SangfA binding induces a dual dynamic response: local rigidification of the active-site β2-β3 loop, residues 100-102 and 108-111 with a coil‑to‑β-strand transition (β-sheet content rises from 28.0% to 32.3%), alongside enhanced mobility in distal loops and a 1.1‑fold expansion of the conformational ensemble. Principal component analysis shows redistribution of motions from a single dominant mode (apo PC1 = 44.2%) to more diffuse fluctuations (holo PC1 = 30.4%), increasing configurational entropy. The ligand forms a dynamic hydrogen‑bond network (1-2 persistent bonds) anchored by Arg55 and hydrophobic contacts with Phe60 and Lys105, while Arg55 remains uninvolved. The computed binding free energy (ΔG = -20.45 ± 3.07 Kcal/mol) accords with picomolar potency. SangfA acts via conformational selection, stabilizing a pre‑existing CypA substate with augmented β-structure and broader dynamics. This entropically driven mechanism challenges static inhibition paradigms. Future efforts should validate the β2-β3 loop transition experimentally and exploit the Lys105 contact to design next‑generation cyclophilin inhibitors.

Indexed as

Cyclophilin ALactonesMolecular Dynamics SimulationProtein BindingProtein Structure, SecondarySpiro CompoundsThermodynamicsCyclophilin ALactonessanglifehrin ASpiro Compounds

Identifiers

PMID42771608
PMCPMC13596834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.